HK1253587A1 - 自分泌運動因子抑制劑及其用途 - Google Patents

自分泌運動因子抑制劑及其用途

Info

Publication number
HK1253587A1
HK1253587A1 HK18112793.4A HK18112793A HK1253587A1 HK 1253587 A1 HK1253587 A1 HK 1253587A1 HK 18112793 A HK18112793 A HK 18112793A HK 1253587 A1 HK1253587 A1 HK 1253587A1
Authority
HK
Hong Kong
Prior art keywords
autotaxin inhibitors
autotaxin
inhibitors
Prior art date
Application number
HK18112793.4A
Other languages
English (en)
Inventor
Gretchen Bain
Jillian Frances Evans
John Howard Hutchinson
David Lonergan
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Publication of HK1253587A1 publication Critical patent/HK1253587A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
HK18112793.4A 2015-05-27 2018-10-08 自分泌運動因子抑制劑及其用途 HK1253587A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562167216P 2015-05-27 2015-05-27

Publications (1)

Publication Number Publication Date
HK1253587A1 true HK1253587A1 (zh) 2019-06-21

Family

ID=57393709

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112793.4A HK1253587A1 (zh) 2015-05-27 2018-10-08 自分泌運動因子抑制劑及其用途

Country Status (15)

Country Link
US (2) US10632104B2 (zh)
EP (2) EP4026549A1 (zh)
JP (2) JP6873919B2 (zh)
KR (1) KR20180026390A (zh)
CN (2) CN116059203A (zh)
AU (3) AU2016268250B2 (zh)
BR (1) BR122023011445B1 (zh)
CA (1) CA2986759A1 (zh)
EA (2) EA036337B1 (zh)
ES (1) ES2915267T3 (zh)
HK (1) HK1253587A1 (zh)
IL (2) IL280863B1 (zh)
MX (2) MX2017015225A (zh)
SG (1) SG10201911204WA (zh)
WO (1) WO2016191427A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055213T2 (hu) 2013-11-22 2021-11-29 Sabre Therapeutics Llc Autotaxin inhibitor vegyületek
MX2017015225A (es) 2015-05-27 2018-02-19 Pharmakea Inc Inhibidores de la autotaxina y sus usos.
CN107021915A (zh) * 2017-04-27 2017-08-08 李亚庆 一种治疗妇科炎症的化合物及制备方法和应用
CA3072346A1 (en) * 2017-08-14 2019-02-21 Camp4 Therapeutics Corporation Methods of treating liver diseases
WO2019172651A1 (ko) 2018-03-06 2019-09-12 주식회사 엘지화학 편광판 및 이를 포함하는 화상 표시 장치
CN112190708B (zh) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
WO2023215196A1 (en) * 2022-05-03 2023-11-09 Sabre Therapeutics Llc Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat
WO2023215684A1 (en) * 2022-05-05 2023-11-09 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210574A (en) 1991-03-08 1993-05-11 Mita Industrial Co., Ltd. Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum
US5186522A (en) 1991-09-24 1993-02-16 Midland Brake, Inc. Air dryer purge line
AU663990B2 (en) 1992-11-10 1995-10-26 Caterpillar Inc. Solenoid valve assembly
US5407368A (en) 1992-12-15 1995-04-18 Minnesota Mining And Manufacturing Company Electrode connector
US5761473A (en) 1993-01-08 1998-06-02 International Business Machines Corporation Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking
US5564949A (en) 1995-01-05 1996-10-15 Thomas & Betts Corporation Shielded compact data connector
JP2664048B2 (ja) 1995-03-27 1997-10-15 科学技術庁金属材料技術研究所長 六フッ化二ケイ素の合成法
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
EP1335923B1 (en) 2000-10-03 2006-07-12 Lilly Icos LLC Condensed pyridoindole derivatives
WO2002083126A1 (en) 2001-04-11 2002-10-24 Idenix (Cayman) Limited Phenylindoles for the treatment of hiv
CA2461670A1 (en) 2001-09-27 2003-04-10 F. Hoffmann-La Roche Ag Indole derivatives as cox ii inhibitors
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
EP1546142A4 (en) 2002-08-29 2007-10-17 Merck & Co Inc INDOLES HAVING ANTIDIABETIC EFFECT
WO2004020408A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
US7060697B2 (en) 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
BRPI0417858B1 (pt) 2003-12-23 2017-10-10 H. Lundbeck A/S Derivative compounds of aniline and pharmaceutical composition that understand it
CN1957117A (zh) 2004-05-19 2007-05-02 住友电气工业株式会社 Ⅲ族氮化物半导体晶体和其制造方法以及ⅲ族氮化物半导体器件
KR101141650B1 (ko) 2004-09-30 2012-05-17 엘지전자 주식회사 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
WO2006050236A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
AR054394A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
WO2007041600A2 (en) 2005-10-03 2007-04-12 Luminescent Technologies, Inc. Mask-pattern determination using topology types
US8722649B2 (en) 2007-06-15 2014-05-13 University Of Utah Research Foundation Alpha-chloro and alpha-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
WO2009151644A2 (en) 2008-06-13 2009-12-17 Yale University Small molecule inhibitors of autotaxin methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
JP5697601B2 (ja) 2008-12-01 2015-04-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対するオータキシン阻害剤としての２，５−ジアミノ−置換ピリド［４，３−ｄ］ピリミジン
EA201101399A1 (ru) 2009-04-02 2012-08-30 Мерк Патент Гмбх Гетероциклические соединения в качестве ингибиторов аутотаксина
SG174518A1 (en) 2009-04-02 2011-10-28 Merck Patent Gmbh Autotaxin inhibitors
US8822476B2 (en) 2009-04-02 2014-09-02 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
US8445200B2 (en) * 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
MX2011011958A (es) 2009-05-11 2012-02-13 Berg Biosystems Llc Metodos para el tratamiento de trastornos metabolicos utilizando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
US8592388B2 (en) 2009-05-20 2013-11-26 Eth Zurich Targeting MicroRNAs for metabolic disorders
WO2011002918A1 (en) 2009-06-30 2011-01-06 The University Of Memphis Research Foundation Novel diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011049433A1 (en) * 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2011116867A1 (de) 2010-03-26 2011-09-29 Merck Patent Gmbh Benzonaphthyridinamine als autotaxin-inhibitoren
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
US9000025B2 (en) 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2012100018A1 (en) 2011-01-20 2012-07-26 University Of Tennessee Research Foundation Inhibitors of autotaxin
CN103476416B (zh) 2011-02-18 2016-09-21 梅迪维新技术公司 治疗高血压的化合物和方法
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
US20140086839A1 (en) * 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
WO2012166415A1 (en) 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
GB2494154B (en) 2011-08-31 2017-11-29 Metaswitch Networks Ltd Conditional telecommunications
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
EP3243815B1 (en) 2011-10-28 2019-07-10 Inhibitaxin Limited Pyridazine derivatives useful in therapy
JP2013129632A (ja) 2011-12-22 2013-07-04 Ono Pharmaceut Co Ltd Ｅｎｐｐ２阻害化合物
US20130270634A1 (en) 2012-04-12 2013-10-17 Richtek Technology Corporation High voltage device and manufacturing method thereof
AU2013276617B9 (en) 2012-06-13 2018-03-29 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
LT2900669T (lt) 2012-09-25 2019-11-11 Hoffmann La Roche Heksahidropirol[3,4-c]pirolo dariniai ir susiję junginai kaip autotaksino (atx) inhibitoriai ir kaip lizofosfatidinės rūgšties (lpa) gamybos inhibitoriai, skirti gydyti pvz., inkstų ligas
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
JP6363616B2 (ja) 2012-12-19 2018-07-25 ノバルティス アーゲー オートタキシン阻害剤
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
WO2015042052A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
JP2016531874A (ja) * 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
SI3066079T1 (sl) 2013-11-05 2018-09-28 Bayer Cropscience Ag Nove spojine za boj proti členonožcem
CL2016001118A1 (es) 2013-11-22 2016-12-02 Basf Se Compuestos heterocíclicos de n-acilimino
WO2015077502A1 (en) 2013-11-22 2015-05-28 Pharmakea, Inc. Tetracyclic autotaxin inhibitors
HUE055213T2 (hu) 2013-11-22 2021-11-29 Sabre Therapeutics Llc Autotaxin inhibitor vegyületek
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
MX2017015225A (es) 2015-05-27 2018-02-19 Pharmakea Inc Inhibidores de la autotaxina y sus usos.

Also Published As

Publication number Publication date
JP7274521B2 (ja) 2023-05-16
US20180147185A1 (en) 2018-05-31
JP6873919B2 (ja) 2021-05-19
EP3302490A1 (en) 2018-04-11
EP3302490A4 (en) 2019-01-23
JP2021119158A (ja) 2021-08-12
CN116059203A (zh) 2023-05-05
US10632104B2 (en) 2020-04-28
AU2020239656A1 (en) 2020-10-15
EP3302490B1 (en) 2022-04-13
IL255764B (en) 2021-03-25
BR112017025420A2 (pt) 2018-08-07
AU2020239656B2 (en) 2022-06-16
IL280863A (en) 2021-04-29
IL255764A (en) 2018-01-31
EA036337B1 (ru) 2020-10-28
ES2915267T3 (es) 2022-06-21
AU2016268250A1 (en) 2017-12-14
AU2022228098A1 (en) 2022-09-29
JP2018515556A (ja) 2018-06-14
WO2016191427A1 (en) 2016-12-01
US20200215034A1 (en) 2020-07-09
IL280863B1 (en) 2024-03-01
EA202091731A1 (ru) 2020-11-30
KR20180026390A (ko) 2018-03-12
EA039684B1 (ru) 2022-02-28
MX2017015225A (es) 2018-02-19
CN107921048A (zh) 2018-04-17
MX2022007436A (es) 2022-07-19
EA201792604A1 (ru) 2018-04-30
AU2016268250B2 (en) 2020-08-27
BR122023011445B1 (pt) 2024-02-27
CA2986759A1 (en) 2016-12-01
SG10201911204WA (en) 2020-02-27
EP4026549A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
IL280863A (en) Ototaxin inhibitors and their uses
GB201605126D0 (en) Inhibitors and their uses
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
SG11201706029VA (en) Anti-senescence compounds and uses thereof
HK1246780A1 (zh) 氮雜-吡啶酮化合物及其用途
ZA201705456B (en) Benzoxaborole compounds and uses thereof
IL253471B (en) Ototaxin inhibitors
HK1247122A1 (zh) 組合及其用途
IL254241A0 (en) Etv2 and its uses
HK1250926A1 (zh) 抑制劑及其應用
IL253459A0 (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
IL258458B (en) Peroxyhemiacetal profragrant and proflavor compounds
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses